Ruxolitinib topical cream 1.5%
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Ruxolitinib topical cream 1.5%, covering 2024-11-05 to 2024-11-05. Get the full timeline:
Most recent: Clinical Trial Update: A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis. [Phase 1]